Clinical trials: Dissection of Aorta, Thoracic
Relapsed Small Cell Lung Cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of…
- Trial name
- NCT05153239
- Testing
- Irinotecan, Lurbinectedin, Topotecan
- Where
- 210 sites in United States, Australia and 22 more
- Volunteers
- 705 people
- Sponsor
- PharmaMar
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Lung Cancer, Head and Neck Cancer
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3…
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity
- Trial name
- NCT01451853
- Testing
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose
- Where
- United States
- Sponsor
- Sound Pharmaceuticals, Incorporated
Recurrent Small Cell Lung Cancer
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine (SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has progressed or recurred following standard…
- Trial name
- NCT01901653
- Testing
- Rovalpituzumab tesirine (SC16LD6.5)
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Stemcentrx
Aortic Aneurysm, Thoracic
Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
The purpose of this study is to assess the feasibility of the use of the GORE® TAG® Thoracic Branch Endoprosthesis to treat aneurysms involving the proximal Descending Thoracic Aorta (DTA)
- Trial name
- NCT02021812
- Testing
- GORE® TAG® Thoracic Branch Endoprosthesis
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- W.L.Gore & Associates
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung…
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
- Trial name
- NCT07625644
- Testing
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 550 people
- Sponsor
- SystImmune Inc.
Carcinoma, Non-Small-Cell Lung
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
- Trial name
- NCT07489066
- Testing
- PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, Breast Cancer
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human…
- Trial name
- NCT02779751
- Testing
- Abemaciclib, Pembrolizumab, Anastrozole
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer, KRAS Activating Mutation
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.
- Trial name
- RAMP202 (NCT04620330)
- Testing
- avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib
- Where
- 45 sites in United States, France and 3 more
- Volunteers
- 90 people
- Sponsor
- Verastem, Inc.
Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs)
MBA Early Feasibility Study
The MBA 25-04 study is a prospective, multicenter, non-randomized, single-arm, early feasibility study designed to assess the initial safety of the MBA device through five years following the index endovascular procedure.
- Conditions
- Thoracic Aortic Aneurysm, Penetrating Aortic Ulcers (PAUs), Thoracic Aortic Dissection, Pseudoaneurysm
- Trial name
- NCT07564375
- Testing
- GORE® Multibranch Arch Endoprosthesis, GORE® Ascending Stent Graft
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- W.L.Gore & Associates
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT02498665
- Testing
- DSP-7888 Dosing Emulsion
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Esophageal Cancers, Advanced Non-small Cell Lung Cancer (NSCLC)
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer.
- Trial name
- NCT06773507
- Testing
- BC008-1A 900mg, BC008-1A 1200mg
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
NSCLC, Lung Cancer, Non-small Cell
Immunotherapy With Racotumomab in Advanced Lung Cancer
This is a prospective, randomized, open label, parallel-group, multicenter phase III study to evaluate the efficacy and safety of active specific immunotherapy with racotumomab plus best supportive care versus best supportive…
- Trial name
- NCT01460472
- Testing
- Racotumomab, Best Support Treatment
- Where
- 46 sites in Argentina, Brazil and 5 more
- Volunteers
- 1,082 people
- Sponsor
- Recombio SL
Carcinoma
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany.
- Trial name
- NCT02303353
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- SPGO Research Mannheim GmbH
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Chest Wall Deformity, Prominent Lower Rib Cage
Prospective Evaluation of Anterior Aesthetic Rib Cage Remodeling With Osteosynthesis for Lower Anterior Thoracic Prominence
This prospective single-group study will evaluate anterior aesthetic rib cage remodeling with osteosynthesis (ARCO) in adults with anteroinferior rib prominence or deformity.
- Trial name
- NCT07813234
- Testing
- Anterior Aesthetic Rib Cage Remodeling With Osteosynthesis, Chest CT and Spirometry Follow-up
- Where
- Colombia
- Volunteers
- 160 people
- Sponsor
- Research Inc
Small-cell Lung Cancer
Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer
LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination with chemotherapy in patients with extensive…
- Trial name
- NCT04740021
- Testing
- LP002, Carboplatin, Etoposide
- Where
- 8 sites in China
- Volunteers
- 46 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Non-small Cell Lung Cancer Stage IV
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of anti-cancer therapy.
- Trial name
- NCT02047344
- Testing
- Antroquinonol
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 31 people
- Sponsor
- Golden Biotechnology Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.